ClinicalTrials.gg
CompletedNCT00626431Updated Jul 19, 2011Results posted

A Study of Leuprolide to Treat Prostate Cancer

A Phase 3 interventional study of Leuprolide acetate - Formulation A and Leuprolide acetate - Formulation B in Prostate Cancer, sponsored by Abbott. Completed at 63 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-19.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
310
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.

Enrollment
10th of 69
310 · median 77
Started
2008
with 2 others
Phase 3
26 of 70
3 open now
Registered
16th of 70
by date
Lead sponsor
2 of 70
Abbott

Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 10th largest by enrollment of the 69 interventional ones that give a count, is one of 3 that started in 2008, is one of 26 in phase 3, and was the 16th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing leuprolide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

To assess the efficacy and safety of 2 new formulations of leuprolide acetate 45 mg 6-month depot, Formulation A or Formulation B, for the treatment of patients with prostate cancer. A formulation will be deemed successful if the percentage of subjects with suppression of testosterone to \<= 50 ng/dL from Week 4 to Week 48 is not less than 87%, (the lower bound of the 2-sided 90% confidence interval), a protocol-specified criterion.

Read the detailed description

A total of 300 male subjects were planned to be enrolled. Subjects were to receive a total of 2 intramuscular (IM) injections of the same formulation, either Formulation A or Formulation B, administered 24 weeks apart. The first 150 subjects were to receive Formulation A for both injections and the next 150 subjects were to receive Formulation B for both injections. The sponsor was to conduct an ongoing review of the primary endpoint data (suppression of testosterone \<= 50 ng/dL) and planned to stop enrollment of Formulation A or Formulation B, or not to administer the second injection of Formulation A or Formulation B, if 15 or more subjects did not achieve testosterone suppression by Week 4 or failed to maintain testosterone suppression during the treatment period.

All analyses and summaries were to be conducted separately for subjects who received Formulation A or Formulation B.

This study was to be conducted at approximately 60-80 investigative sites. Subjects participated in the trial for approximately 14 months.

This trial was to include a Screening Period (up to 4 weeks), a 12-month Treatment Period (two 6-month treatment cycles), and a Follow-Up Period (30 days).

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Lupron Depot
  • prostate cancer
  • leuprolide acetate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily sign an IRB-approved form and any required privacy statement/authorization form.
  • Pre-trial serum testosterone level >150 ng/dL.
  • -confirmed prostatic adenocarcinoma in Jewett Clinical Stage A2, B, C or D and TNM* classification cT1b-4, N: any, M: any.

    *Tumor/Nodes/

  • Subjects with a rising PSA following radical prostatectomy defined as an increase of 0.2 ng/mL from the previous test on two consecutive testings or rising PSA following prostate irradiation using Phoenix Definition of a rise of greater than or equal to 2.0 ng/mL above the nadir.
  • Prostate cancer and general clinical status is sufficient to warrant at least 48 weeks of continuous androgen deprivation treatment, without concomitant antiandrogen treatment.
  • (ECOG) Performance status grades 0,1,or 2 at the time of pre-trial screening.
  • of at least 18 months.
  • Subjects with serum creatinine ≤1.9 mg/dL, ≤2.0 mg/dL (unless Gilbert's syndrome with normal , ALT); AST and ALT ≤2.5 times the .

Exclusion criteria

Exclusion Criteria:

  • Requires additional treatment including radical prostatectomy, radiotherapy or cryotherapy of local disease.
  • Historical, clinical, or radiographic evidence of central nervous system , including spinal cord metastasis.
  • Clinical evidence of urinary tract obstruction.
  • History of bilateral orchiectomy, adrenalectomy, or hypophysectomy.
  • History of clinical hypogonadism.
  • Current or history of malignancy except for prostate cancer or basal or squamous cell carcinoma of the skin.
  • Clinical or laboratory evidence of any severe underlying disease state (excluding prostate cancer) that would place subjects in additional jeopardy by participating in this trial.
  • to leuprolide, polylactic acid, or any of the drug.
  • Incomplete recovery from the effects of any major surgery.
  • History of receiving of the following prostate cancer therapies within 8 weeks prior to the Screening Visit: chemotherapy, immunotherapy, antiandrogen, radiation therapy, cryotherapy, strontium, or biological response modifiers.
  • History of prostatic surgery within 4 weeks prior to the Screening Visit.
  • Received hormonal therapy, including GnRH analogs (less than or equal to 6 month depot administration), estrogen, Megace and phytotherapy, within 32 weeks prior to the Screening Visit and during the trial.
  • Alternative medical therapies which have an estrogenic, androgenic, or antiandrogenic effect (including phyto-estrogens and phyto-androgens) within 12 weeks prior to the Screening Visit and during the trial.
  • Requires the chronic use of systemic and anticonvulsants that may affect bone loss such as carbamazepine, phenobarbital, phenytoin, valproic acid or primidone.
  • May require antiandrogen, immuno-, or surgical therapy for prostate cancer during the trial.
  • History of alcoholism or consumes >14 alcoholic beverages per week or illicit drug abuse within 12 months prior to screening.
  • Received therapy with a GnRH analog (1 year implant) within 60 weeks prior to the Screening Visit.
  • Received therapy with finasteride or ketoconazole within 1 week prior to the Screening Visit; dutasteride within 25 weeks prior to the Screening Visit.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
310 participants (actual)

Study arms

  • Experimental
    Leuprolide acetate - Formulation A

    Leuprolide acetate 45 mg, 6-month depot

    Drug: Leuprolide acetate - Formulation A

  • Experimental
    Leuprolide acetate - Formulation B

    Leuprolide acetate, 45 mg, 6-month depot

    Drug: Leuprolide acetate - Formulation B

Interventions

  • Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation A, 45 mg 6 month depot, 24 weeks apart.

    Also known as: Lupron, leuprorelin, gonadotropin hormone-releasing hormone (GnRH), luteinizing hormone-releasing hormone (LHRH)

  • Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation B, 45 mg 6 month depot, 24 weeks apart.

    Also known as: Lupron, leuprorelin, gonadotropin hormone-releasing hormone (GnRH), luteinizing hormone-releasing hormone (LHRH)

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: Intent-to-treat (ITT) Population for the Primary Endpoint.

    The percentage of subjects with testosterone suppression (\<= 50 ng/dL) from Week 4 to Week 48 was calculated by the Kaplan-Meier method for right-censored observations. Subjects who failed testosterone suppression were considered failures on the first day of a testosterone measurement (\>50 ng/dL). Subjects who prematurely discontinued without escaping and those who were successfully suppressed through Week 48 were censored at their last measured testosterone value (Day 337 to Day 340 at Week 48). The 90% 2-sided confidence interval was calculated from Kaplan-Meier estimates.

    Time frame: Week 4 to Week 48

  2. Adjusted Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: ITT Population for the Primary Endpoint Adjusted

    The adjusted percentage of subjects with testosterone suppression (\<= 50 ng/dL) from Week 4 to Week 48 was calculated by the Kaplan-Meier method for right-censored observations. The primary efficacy analysis was adjusted to censor subjects who received an anti-androgen at the last testosterone measurement before use of the anti-androgen. One additional subject was censored because of a laboratory error, at the last measurement before the error. The adjusted 90% 2-sided confidence interval was calculated from Kaplan-Meier estimates.

    Time frame: Week 4 to Week 48

  3. Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation B: ITT Population for the Primary Endpoint Preplanned

    The percentage of subjects with testosterone suppression (\<= 50 ng/dL) from Week 4 to Week 48 was calculated by the Kaplan-Meier method for right-censored observations. Subjects who failed testosterone suppression were considered failures on the first day of a testosterone measurement (\>50 ng/dL). Subjects who prematurely discontinued without escaping and those who were successfully suppressed through Week 48 were censored at their last measured testosterone value (Day 337 to Day 340 at Week 48). The 90% 2-sided confidence interval was calculated from Kaplan-Meier estimates.

    Time frame: Week 4 to Week 48

Secondary outcomes

  1. Mean Testosterone Concentration (+/- Standard Error) at Each Visit for Formulation A: ITT Population

    Baseline was the last measurement before the first dose of Formulation A. The mean +/- standard error was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.

    Time frame: Baseline, Days 2 and 8, Weeks 2, 4, 8, 14, 20, 24, 26, 30, 34, 40, 46, 48, and Final Visit

  2. Mean Testosterone Concentration (+/- Standard Error) at Each Visit for Formulation B: ITT Population

    Baseline was the last measurement before the first dose of Formulation B. The mean +/- standard error was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.

    Time frame: Baseline, Days 2 and 8, Weeks 2, 4, 8, 14, 20, 24, 26, 30, 34, 40, 46, 48, and Final Visit

  3. Mean (+/- Standard Error) Acute-on-chronic Changes in Testosterone From Pre-injection Levels for Formulation A: ITT Population

    The acute-on-chronic effect is an agonistic stimulation of serum testosterone after the second depot injection of Formulation A. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.

    Time frame: Week 24 before the second injection until 2 weeks after Week 24 (2 hours [h], 4 h, 8 h, 1 day [d], 2 d, 3-10 d, and 11-17 d postdose)

  4. Mean (+/- Standard Error) Acute-on-chronic Changes in Testosterone From Pre-injection Levels for Formulation B: ITT Population

    The acute-on-chronic effect is an agonistic stimulation of serum testosterone after the second depot injection of Formulation B. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.

    Time frame: Week 24 before the second injection until 2 weeks after Week 24 (2 h, 4 h, 8 h, 1 d, 2 d, 3-10 d, and 11-17 d postdose)

  5. Mean (+/- Standard Error) Acute-on-chronic Changes in Luteinizing Hormone From Pre-injection Levels for Formulation A: ITT Population

    The acute-on-chronic effect is an agonistic stimulation of luteinizing hormone after the second depot injection of Formulation A. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.

    Time frame: Week 24 before the second injection until 2 weeks after Week 24 (2 h, 4 h, 8 h, 1 d, 2 d, 3-10 d, and 11-17 d postdose)

  6. Mean (+/- Standard Error) Acute-on-chronic Changes in Luteinizing Hormone From Pre-injection Levels for Formulation B: ITT Population

    The acute-on-chronic effect is an agonistic stimulation of luteinizing hormone after the second depot injection of Formulation B. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.

    Time frame: Week 24 before the second injection until 2 weeks after Week 24 (2 h, 4 h, 8 h, 1 d, 2 d, 3-10 d, and 11-17 d postdose)

  7. Mean (+/- Standard Error) Prostate Specific Antigen (PSA) at Baseline, Visits Throughout the Study, and at Final Visit for Formulation A: ITT Population

    PSA levels were measured at baseline and each treatment visit for Formulation A. The mean (+/- standard error) was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.

    Time frame: Baseline, Day 8, Week 14, Week 24, Week 30, Week 40, Week 48, and the Final Visit

  8. Mean (+/- Standard Error) Prostate Specific Antigen (PSA) at Baseline, Visits Throughout the Study, and at Final Visit for Formulation B: ITT Population

    PSA levels were measured at baseline and each treatment visit for Formulation B. The mean (+/- standard error) was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.

    Time frame: Baseline, Day 8, Week 14, Week 24, Week 30, Week 40, Week 48, and the Final Visit

07

Results

Posted Nov 1, 2010
Limitations and caveats
Treatment with Formulation B was prematurely discontinued as testosterone was not adequately suppressed to \<= 50 ng/dL or escapes from suppression occurred. Subjects who had not received dose 2 of Formulation B were discontinued after Week 24.

Participant flow

The enrollment of subjects with Formulation A occurred sequentially before the enrollment of subjects with Formulation B.

Participant flow — Overall Study
MilestoneLeuprolide Acetate - Formulation ALeuprolide Acetate - Formulation B
Started151159
Completed134114
Not completed1745

Outcome measures

PrimaryPercentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: Intent-to-treat (ITT) Population for the Primary Endpoint.

The percentage of subjects with testosterone suppression (\<= 50 ng/dL) from Week 4 to Week 48 was calculated by the Kaplan-Meier method for right-censored observations. Subjects who failed testosterone suppression were considered failures on the first day of a testosterone measurement (\>50 ng/dL). Subjects who prematurely discontinued without escaping and those who were successfully suppressed through Week 48 were censored at their last measured testosterone value (Day 337 to Day 340 at Week 48). The 90% 2-sided confidence interval was calculated from Kaplan-Meier estimates.

Time frame:
Week 4 to Week 48
Reported as:
Number · Percent Suppressed
Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: Intent-to-treat (ITT) Population for the Primary Endpoint.
Percent SuppressedLeuprolide Acetate - Formulation A
Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: Intent-to-treat (ITT) Population for the Primary Endpoint.93.6 ± 2.05
SecondaryMean Testosterone Concentration (+/- Standard Error) at Each Visit for Formulation A: ITT Population

Baseline was the last measurement before the first dose of Formulation A. The mean +/- standard error was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.

Time frame:
Baseline, Days 2 and 8, Weeks 2, 4, 8, 14, 20, 24, 26, 30, 34, 40, 46, 48, and Final Visit
Reported as:
Mean · ng/dL
Mean Testosterone Concentration (+/- Standard Error) at Each Visit for Formulation A: ITT Population
ng/dLLeuprolide Acetate - Formulation A
Testosterone concentration at baseline432.9 ± 14.35
Testosterone concentration at Day 2613.1 ± 21.53
Testosterone concentration at Day 8468.2 ± 16.55
Testosterone concentration at Week 2127.1 ± 7.36
Testosterone concentration at Week 416.0 ± 0.70
Testosterone concentration at Week 89.6 ± 0.46
Testosterone concentration at Week 149.2 ± 0.46
Testosterone concentration at Week 208.5 ± 0.46
Testosterone concentration at Week 2414.3 ± 1.25
Testosterone concentration at Week 269.0 ± 0.47
Testosterone concentration at Week 309.9 ± 1.67
Testosterone concentration at Week 3413.0 ± 4.14
Testosterone concentration at Week 408.8 ± 0.41
Testosterone concentration at Week 468.8 ± 0.46
Testosterone concentration at Week 48/Final Visit13.3 ± 3.67
SecondaryMean Testosterone Concentration (+/- Standard Error) at Each Visit for Formulation B: ITT Population

Baseline was the last measurement before the first dose of Formulation B. The mean +/- standard error was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.

Time frame:
Baseline, Days 2 and 8, Weeks 2, 4, 8, 14, 20, 24, 26, 30, 34, 40, 46, 48, and Final Visit
Reported as:
Mean · ng/dL
Mean Testosterone Concentration (+/- Standard Error) at Each Visit for Formulation B: ITT Population
ng/dLLeuprolide Acetate - Formulation B
Testosterone concentration at baseline414.0 ± 14.15
Testosterone concentration at Day 2578.0 ± 20.14
Testosterone concentration at Day 8466.9 ± 17.70
Testosterone concentration at Week 2127.4 ± 7.35
Testosterone concentration at Week 415.3 ± 0.71
Testosterone concentration at Week 89.1 ± 0.44
Testosterone concentration at Week 148.9 ± 0.42
Testosterone concentration at Week 209.6 ± 0.54
Testosterone concentration at Week 2428.0 ± 3.97
Testosterone concentration at Week 2615.6 ± 2.63
Testosterone concentration at Week 309.4 ± 0.60
Testosterone concentration at Week 349.7 ± 0.53
Testosterone concentration at Week 409.5 ± 0.52
Testosterone concentration at Week 469.4 ± 0.64
Testosterone concentration at Week 48/Final Visit13.8 ± 1.87
SecondaryMean (+/- Standard Error) Acute-on-chronic Changes in Testosterone From Pre-injection Levels for Formulation A: ITT Population

The acute-on-chronic effect is an agonistic stimulation of serum testosterone after the second depot injection of Formulation A. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.

Time frame:
Week 24 before the second injection until 2 weeks after Week 24 (2 hours [h], 4 h, 8 h, 1 day [d], 2 d, 3-10 d, and 11-17 d postdose)
Reported as:
Mean · ng/dL
Mean (+/- Standard Error) Acute-on-chronic Changes in Testosterone From Pre-injection Levels for Formulation A: ITT Population
ng/dLLeuprolide Acetate - Formulation A
Testosterone concentration at 2 hours postdose-1.9 ± 0.85
Testosterone concentration at 4 hours postdose-1.2 ± 0.93
Testosterone concentration at 8 hours postdose-1.3 ± 1.02
Testosterone concentration at Day 1 postdose-0.1 ± 0.95
Testosterone concentration at Day 2 postdose-0.1 ± 0.92
Testosterone concentration at Days 3-10 postdose-1.0 ± 0.89
Testosterone concentration at Days 11-17 postdose-2.1 ± 0.87
SecondaryMean (+/- Standard Error) Acute-on-chronic Changes in Testosterone From Pre-injection Levels for Formulation B: ITT Population

The acute-on-chronic effect is an agonistic stimulation of serum testosterone after the second depot injection of Formulation B. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.

Time frame:
Week 24 before the second injection until 2 weeks after Week 24 (2 h, 4 h, 8 h, 1 d, 2 d, 3-10 d, and 11-17 d postdose)
Reported as:
Mean · ng/dL
Mean (+/- Standard Error) Acute-on-chronic Changes in Testosterone From Pre-injection Levels for Formulation B: ITT Population
ng/dLLeuprolide Acetate - Formulation B
Testosterone concentration at 2 hours postdose-0.7 ± 0.66
Testosterone concentration at 4 hours postdose1.6 ± 1.13
Testosterone concentration at 8 hours postdose3.6 ± 1.35
Testosterone concentration at Day 1 postdose8.0 ± 1.80
Testosterone concentration at Day 2 postdose7.8 ± 1.81
Testosterone concentration at Days 3-10 postdose4.5 ± 1.07
Testosterone concentration at Day 11-17 postdose-4.2 ± 1.43
PrimaryAdjusted Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: ITT Population for the Primary Endpoint Adjusted

The adjusted percentage of subjects with testosterone suppression (\<= 50 ng/dL) from Week 4 to Week 48 was calculated by the Kaplan-Meier method for right-censored observations. The primary efficacy analysis was adjusted to censor subjects who received an anti-androgen at the last testosterone measurement before use of the anti-androgen. One additional subject was censored because of a laboratory error, at the last measurement before the error. The adjusted 90% 2-sided confidence interval was calculated from Kaplan-Meier estimates.

Time frame:
Week 4 to Week 48
Reported as:
Number · Percent Suppressed
Adjusted Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: ITT Population for the Primary Endpoint Adjusted
Percent SuppressedLeuprolide Acetate - Formulation A
Adjusted Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: ITT Population for the Primary Endpoint Adjusted93.4 (89.9 to 96.9)
SecondaryMean (+/- Standard Error) Acute-on-chronic Changes in Luteinizing Hormone From Pre-injection Levels for Formulation A: ITT Population

The acute-on-chronic effect is an agonistic stimulation of luteinizing hormone after the second depot injection of Formulation A. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.

Time frame:
Week 24 before the second injection until 2 weeks after Week 24 (2 h, 4 h, 8 h, 1 d, 2 d, 3-10 d, and 11-17 d postdose)
Reported as:
Mean · ng/dL
Mean (+/- Standard Error) Acute-on-chronic Changes in Luteinizing Hormone From Pre-injection Levels for Formulation A: ITT Population
ng/dLLeuprolide Acetate - Formulation A
Testosterone concentration at 2 hours postdose0.2 ± 0.03
Testosterone concentration at 4 hours postdose0.2 ± 0.03
Testosterone concentration at 8 hours postdose0.2 ± 0.02
Testosterone concentration at Day 1 postdose0.2 ± 0.02
Testosterone concentration at Day 2 postdose0.1 ± 0.01
Testosterone concentration at Days 3-10 postdose0.1 ± 0.01
Testosterone concentration at Days 11-17 postdose0.1 ± 0.02
SecondaryMean (+/- Standard Error) Acute-on-chronic Changes in Luteinizing Hormone From Pre-injection Levels for Formulation B: ITT Population

The acute-on-chronic effect is an agonistic stimulation of luteinizing hormone after the second depot injection of Formulation B. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.

Time frame:
Week 24 before the second injection until 2 weeks after Week 24 (2 h, 4 h, 8 h, 1 d, 2 d, 3-10 d, and 11-17 d postdose)
Reported as:
Mean · ng/dL
Mean (+/- Standard Error) Acute-on-chronic Changes in Luteinizing Hormone From Pre-injection Levels for Formulation B: ITT Population
ng/dLLeuprolide Acetate - Formulation B
Testosterone concentration at 2 hours postdose0.4 ± 0.07
Testosterone concentration at 4 hours postdose0.5 ± 0.12
Testosterone concentration at 8 hours postdose0.4 ± 0.11
Testosterone concentration at Day 1 postdose0.4 ± 0.08
Testosterone concentration at Day 2 postdose0.2 ± 0.04
Testosterone concentration at Days 3-10 postdose0.1 ± 0.02
Testosterone concentration at Days 11-17 postdose-0.1 ± 0.04
SecondaryMean (+/- Standard Error) Prostate Specific Antigen (PSA) at Baseline, Visits Throughout the Study, and at Final Visit for Formulation A: ITT Population

PSA levels were measured at baseline and each treatment visit for Formulation A. The mean (+/- standard error) was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.

Time frame:
Baseline, Day 8, Week 14, Week 24, Week 30, Week 40, Week 48, and the Final Visit
Reported as:
Mean · ng/mL
Mean (+/- Standard Error) Prostate Specific Antigen (PSA) at Baseline, Visits Throughout the Study, and at Final Visit for Formulation A: ITT Population
ng/mLLeuprolide Acetate - Formulation A
PSA concentration at baseline35.0 ± 11.21
PSA Concentration at Day 840.4 ± 12.90
PSA Concentration at Week 142.4 ± 0.62
PSA Concentration at Week 242.9 ± 1.09
PSA Concentration at Week 301.6 ± 0.46
PSA Concentration at Week 402.2 ± 0.82
PSA Concentration at Week 48/Final Visit3.7 ± 1.51
SecondaryMean (+/- Standard Error) Prostate Specific Antigen (PSA) at Baseline, Visits Throughout the Study, and at Final Visit for Formulation B: ITT Population

PSA levels were measured at baseline and each treatment visit for Formulation B. The mean (+/- standard error) was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.

Time frame:
Baseline, Day 8, Week 14, Week 24, Week 30, Week 40, Week 48, and the Final Visit
Reported as:
Mean · ng/mL
Mean (+/- Standard Error) Prostate Specific Antigen (PSA) at Baseline, Visits Throughout the Study, and at Final Visit for Formulation B: ITT Population
ng/mLLeuprolide Acetate - Formulation B
PSA concentration at baseline20.5 ± 3.88
PSA Concentration at Day 823.1 ± 4.03
PSA Concentration at Week 142.4 ± 0.51
PSA Concentration at Week 242.5 ± 0.65
PSA Concentration at Week 302.7 ± 0.86
PSA Concentration at Week 402.5 ± 0.85
PSA Concentration at Week 48/Final Visit6.2 ± 2.75
PrimaryPercentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation B: ITT Population for the Primary Endpoint Preplanned

The percentage of subjects with testosterone suppression (\<= 50 ng/dL) from Week 4 to Week 48 was calculated by the Kaplan-Meier method for right-censored observations. Subjects who failed testosterone suppression were considered failures on the first day of a testosterone measurement (\>50 ng/dL). Subjects who prematurely discontinued without escaping and those who were successfully suppressed through Week 48 were censored at their last measured testosterone value (Day 337 to Day 340 at Week 48). The 90% 2-sided confidence interval was calculated from Kaplan-Meier estimates.

Time frame:
Week 4 to Week 48
Reported as:
Number · Percent suppressed
Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation B: ITT Population for the Primary Endpoint Preplanned
Percent suppressedLeuprolide Acetate - Formulation B
Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation B: ITT Population for the Primary Endpoint Preplanned86.9 (82.2 to 91.7)

Adverse events

Collected over Both serious adverse events and adverse events were reported from the receipt of the first dose of study drug through the 30-day follow-up period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leuprolide Acetate - Formulation A—31/151 (20.5%)133/151 (88.1%)
Leuprolide Acetate - Formulation B—41/159 (25.8%)127/159 (79.9%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventLeuprolide Acetate - Formulation ALeuprolide Acetate - Formulation B
coronary artery diseaseCardiac disorders3/1512/159
chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders3/1510/159
cardiac failure congestiveCardiac disorders2/1513/159
pneumoniaInfections and infestations2/1513/159
syncopeNervous system disorders0/1513/159
anemiaBlood and lymphatic system disorders2/1510/159
atrial fibrillationCardiac disorders2/1510/159
carotid artery stenosisNervous system disorders2/1510/159
transient ischemic attackNervous system disorders2/1510/159
cholelithiasisHepatobiliary disorders2/1510/159
Most frequent other events
Showing 10 of 24
Most frequent other events
EventLeuprolide Acetate - Formulation ALeuprolide Acetate - Formulation B
hot flushVascular disorders88/15171/159
injection site painGeneral disorders27/15126/159
arthralgiaMusculoskeletal and connective tissue disorders13/15122/159
fatigueGeneral disorders18/15114/159
constipationGastrointestinal disorders15/15116/159
nasopharyngitisInfections and infestations10/15115/159
dizzinessNervous system disorders8/15115/159
hypertensionVascular disorders9/15115/159
insomniaPsychiatric disorders13/1519/159
headacheNervous system disorders11/1519/159

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Leuprolide Acetate - Formulation ALeuprolide Acetate - Formulation BTotal
<=18 years000
Between 18 and 65 years183351
>=65 years133126259
Sex: Female, Male
Sex: Female, Male(Participants)Leuprolide Acetate - Formulation ALeuprolide Acetate - Formulation BTotal
Female000
Male151159310
Region of Enrollment
Region of Enrollment(participants)Leuprolide Acetate - Formulation ALeuprolide Acetate - Formulation BTotal
United States151159310
08

Study locations

63 sites
  • Site Reference ID/Investigator# 8696
    Birmingham, Alabama 35209, United States
  • Site Reference ID/Investigator# 8681
    Homewood, Alabama 35209, United States
  • Site Reference ID/Investigator# 8569
    Anchorage, Alaska 99508, United States
  • Site Reference ID/Investigator# 9709
    Phoenix, Arizona 85013, United States
  • Site Reference ID/Investigator# 8662
    Sierra Vista, Arizona 85635, United States
  • Site Reference ID/Investigator# 8656
    Tucson, Arizona 85710, United States
  • Site Reference ID/Investigator# 9705
    Little Rock, Arkansas 72211, United States
  • Site Reference ID/Investigator# 8691
    Anaheim, California 92801, United States
  • Site Reference ID/Investigator# 8566
    Atherton, California 94027, United States
  • Site Reference ID/Investigator# 8686
    Fresno, California 93720, United States
  • Site Reference ID/Investigator# 8698
    Laguna Hills, California 92653, United States
  • Site Reference ID/Investigator# 9703
    Long Beach, California 90806, United States
  • Site Reference ID/Investigator# 8674
    Los Angeles, California 90015, United States
  • Site Reference ID/Investigator# 8650
    Tarzana, California 91356, United States
  • Site Reference ID/Investigator# 8699
    Torrance, California 90505, United States
  • Site Reference ID/Investigator# 8668
    Denver, Colorado 80211, United States
  • Site Reference ID/Investigator# 8646
    Englewood, Colorado 80113, United States
  • Site Reference ID/Investigator# 8652
    Middlebury, Connecticut 06762, United States
  • Site Reference ID/Investigator# 8697
    New Britain, Connecticut 06052, United States
  • Site Reference ID/Investigator# 8655
    Aventura, Florida 33180, United States
  • Site Reference ID/Investigator# 8648
    Daytona Beach, Florida 32114, United States
  • Site Reference ID/Investigator# 8660
    New Smyrna Beach, Florida 32168, United States
  • Site Reference ID/Investigator# 8658
    Orange City, Florida 32763, United States
  • Site Reference ID/Investigator# 8664
    Orlando, Florida 32803, United States
  • Site Reference ID/Investigator# 8651
    Saint Augustine, Florida 32086, United States
  • Site Reference ID/Investigator# 8661
    St. Petersburg, Florida 33710, United States
  • Site Reference ID/Investigator# 8568
    Tallahassee, Florida 32308, United States
  • Site Reference ID/Investigator# 8679
    Wellington, Florida 33414, United States
  • Site Reference ID/Investigator# 8562
    West Palm Beach, Florida 33407, United States
  • Site Reference ID/Investigator# 8670
    Roswell, Georgia 30076, United States
  • Site Reference ID/Investigator# 9708
    Thomasville, Georgia 31799, United States
  • Site Reference ID/Investigator# 8693
    Fort Wayne, Indiana 46825, United States
  • Site Reference ID/Investigator# 8690
    Newburgh, Indiana 47630, United States
  • Site Reference ID/Investigator# 8565
    Overland Park, Kansas 66211, United States
  • Site Reference ID/Investigator# 8676
    Greenbelt, Maryland 20770, United States
  • Site Reference ID/Investigator# 8653
    Las Vegas, Nevada 89148, United States
  • Site Reference ID/Investigator# 8667
    Lawrenceville, New Jersey 08648, United States
  • Site Reference ID/Investigator# 9702
    Bronx, New York 10461, United States
  • Site Reference ID/Investigator# 8665
    New York, New York 10016, United States
  • Site Reference ID/Investigator# 8657
    Poughkeepsie, New York 12601, United States
  • Site Reference ID/Investigator# 8680
    Charlotte, North Carolina 28209, United States
  • Site Reference ID/Investigator# 8673
    Concord, North Carolina 28025, United States
  • Site Reference ID/Investigator# 8666
    Raleigh, North Carolina 27607, United States
  • Site Reference ID/Investigator# 8570
    Salisbury, North Carolina 28144, United States
  • Site Reference ID/Investigator# 8644
    Winston-Salem, North Carolina 27103, United States
  • Site Reference ID/Investigator# 8663
    Cincinnati, Ohio 45212, United States
  • Site Reference ID/Investigator# 8567
    Columbus, Ohio 43220, United States
  • Site Reference ID/Investigator# 8678
    Bethany, Oklahoma 73008, United States
  • Site Reference ID/Investigator# 8563
    Bala Cynwyd, Pennsylvania 19004, United States
  • Site Reference ID/Investigator# 8692
    Lancaster, Pennsylvania 17604-3200, United States
  • Site Reference ID/Investigator# 8689
    Myrtle Beach, South Carolina 29572, United States
  • Site Reference ID/Investigator# 8643
    Germantown, Tennessee 38138, United States
  • Site Reference ID/Investigator# 8695
    Germantown, Tennessee 38138, United States
  • Site Reference ID/Investigator# 8685
    Memphis, Tennessee 38119, United States
  • Site Reference ID/Investigator# 8564
    Nashville, Tennessee 37209, United States
  • Site Reference ID/Investigator# 8645
    Nashville, Tennessee 37232-2765, United States
  • Site Reference ID/Investigator# 8641
    Dallas, Texas 75231, United States
  • Site Reference ID/Investigator# 8675
    Houston, Texas 77024, United States
  • Site Reference ID/Investigator# 8684
    San Antonio, Texas 78229, United States
  • Site Reference ID/Investigator# 8649
    Tyler, Texas 75701, United States
  • Site Reference ID/Investigator# 8683
    Salt Lake City, Utah 84107, United States
  • Site Reference ID/Investigator# 8672
    Norfolk, Virginia 23502, United States
  • Site Reference ID/Investigator# 8669
    Richmond, Virginia 23235, United States
09

References and documents

Publications

  • Spitz A, Young JM, Larsen L, Mattia-Goldberg C, Donnelly J, Chwalisz K. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer Prostatic Dis. 2012 Mar;15(1):93-9. doi: 10.1038/pcan.2011.50. Epub 2011 Oct 25. PubMed 22025196 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Aug 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2008
First posted
Feb 29, 2008
Start
Feb 2008
Primary completionActual
Aug 2009
CompletionActual
Sep 2009
Results first posted
Nov 1, 2010
Last update
Jul 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00626431
Lead sponsor
Abbott
First posted
Feb 29, 2008
Start date
Feb 2008
Primary completion
Aug 2009
Completion
Sep 2009
Results posted
Nov 1, 2010
Last update
Jul 19, 2011

Study contacts

Kristof Chwalisz, MD, PhD
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion